Quantcast

Sage's depression drug succeeds in mid-stage study


Shutterstock photo

Dec 7 (Reuters) - Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

The 89-patient study testing the drug, SAGE-217, showed statistically significant reduction of depression symptoms, compared to a placebo.


Dec 7 (Reuters) - Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

The 89-patient study testing the drug, SAGE-217, showed statistically significant reduction of depression symptoms, compared to a placebo.




This article appears in: World Markets , Stocks , Economy , Technology
Referenced Symbols: SAGE


More from Reuters

Subscribe






See headlines for SAGE









Research Brokers before you trade

Want to trade FX?